Form 4: Werewolf Therapeutics Director Anil Singhal Receives Stock Option Grants, Correcting Prior Clerical Error

Werewolf Therapeutics, Inc. Director Anil K. Singhal was granted stock options for 17,358 shares of common stock, including options previously delayed due to a clerical error, as disclosed in a recent SEC Form 4 filing.

Summary

• Director Anil K. Singhal of Werewolf Therapeutics, Inc. (HOWL) was granted two tranches of stock options.
• The first grant, dated June 11, 2025, was for 9,000 stock options with an exercise price of $1.23. These options were due to the non-employee director compensation policy but were not previously granted due to a clerical error.
• These 9,000 options will vest one-third on February 19, 2026, with the remainder vesting in equal monthly installments until February 19, 2028, contingent on Mr. Singhal's continued service as a director.
• The second grant, dated June 12, 2025, was for 8,358 stock options with an exercise price of $1.29.
• These 8,358 options will vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or the next annual meeting of stockholders following the grant date, also subject to continued service.
• Both option grants have expiration dates in June 2035.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of director compensation, which is generally positive as it aligns director interests with shareholders. The mention of a clerical error is a minor negative but has been rectified, indicating transparency. Overall, it's a neutral to slightly positive event as it reflects standard corporate governance and compensation practices.

Positives

• The grants align with the company's established non-employee director compensation policy, indicating adherence to standard corporate governance practices.
• The vesting schedules for the options incentivize the director's continued service and align his interests with the company's long-term performance and shareholder value creation.
• The disclosure and rectification of a clerical error demonstrate transparency in reporting and commitment to fulfilling compensation obligations.

Negatives

• A clerical error led to a delay in the initial grant of 9,000 stock options, although this issue has since been rectified.

Future Outlook

The stock options have specific vesting schedules extending to February 2028 and June 2026 (for the second grant's first anniversary/next annual meeting), contingent on the director's continued service, aligning his interests with the company's long-term performance.

Industry Context

This filing represents a routine compensation disclosure for a director in a publicly traded biotechnology company. Stock option grants are a common form of executive and director compensation in the biotech industry, aiming to align leadership interests with shareholder value creation and long-term company performance.

Comparison to Industry Standards

• The granting of stock options to non-employee directors is a standard practice across publicly traded companies, particularly in the biotechnology sector, as a form of long-term incentive compensation.
• The vesting schedules, which are tied to continued service, are typical for such grants, ensuring retention and alignment of director interests with company performance.
• The disclosure of a clerical error and its subsequent correction, while minor, reflects adherence to SEC reporting requirements, which is consistent with good corporate governance standards.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value creation through equity ownership and performance-based vesting, potentially fostering long-term growth.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service by Anil K. Singhal as a director for the options to vest according to their respective schedules.
• Future vesting events for the 9,000 options on February 19, 2026, and subsequent monthly installments until February 19, 2028.
• Future vesting event for the 8,358 options on the earlier of the first anniversary of the grant date (June 12, 2026) or the next annual meeting of stockholders.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Anil K. Singhal, Stock Options, SEC Form 4, Insider Trading, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals